CureVac rises on data from COVID-19 vaccine development program with GSK

CureVac NV

05/01/2024 12:57

** U.S. listed shares of German drugmaker CureVac  5CV.DE 
 CVAC.O  rise 2.1% to $4.30 premarket 
    ** Co announces positive data from its mid-stage trial
testing its COVID-19 vaccine candidates developed in
collaboration with GSK  GSK.L  
    ** The mid-stage study assessed the safety and immune
response of the co's two vaccine candidates against a licensed
mRNA-based COVID-19 vaccine   
    ** Co says both its vaccine candidates showed meaningful
immune responses and favorable tolerability profile 
     ** The vaccine candidates are developed based on CVAC's
second generation mRNA backbone, which can help protect against
one or more emerging COVID-19 variants 
    ** Stock was down 30.1% in 2023 

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))